Gufic BioSciences Fair Value
Gufic BioSciences (GUFICBIO) average fair value is ₹488.73 across 5 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, vs a current market price of ₹288.7 (+69.29%), fair value range ₹29.99–₹1562.6. Examine GUFICBIO quarterly results for recent quarterly revenue, profit and EPS trends.
Fair Value Analysis Export
GUFICBIO Fair Value vs Current Price — Valuation Summary
GUFICBIO average fair value, fair value range, price gap and valuation status across 5 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number. For live price and a broader fundamental view, visit GUFICBIO screener.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
GUFICBIO Fair Value Analysis — Data Sources & Coverage
Gufic BioSciences financial data sources, valuation methods applied and sector benchmarks used — 2025 financial year. See GUFICBIO price to book ratio to compare market price against book value per share.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is from the previous year (2025).
GUFICBIO vs Healthcare Sector Peers — P/E, P/B & Market Cap
Gufic BioSciences P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
| Accretion Pharmaceuticals | ACCPL | 17.91 | 2.7 | ₹120 |
| Jeena Sikho Lifecare | JSLL | 40.38 | 23.07 | ₹7,944 |
| Par Drugs & Chemical | PAR | 8.2 | 0.96 | ₹103 |
| Aurobindo Pharma | AUROPHARMA | 25.16 | 2.5 | ₹87,806 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.